These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38847819)

  • 1. Epidemiology of thyroid-stimulating immunoglobulin in recent-onset symptomatic thyroid eye disease.
    Lai KKH; Aljufairi FMAA; Sebastian JU; Wei Y; Jia R; Chan KKW; Au EYL; Lee ACH; Ng CM; Yuen HKL; Yip WWK; Young AL; Cheng GPM; Tham CCY; Pang CP; Chong KKL
    Eur Thyroid J; 2024 Aug; 13(4):. PubMed ID: 38847819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid stimulating immunoglobulin concentration is associated with disease activity and predicts response to treatment with intravenous methylprednisolone in patients with Graves' orbitopathy.
    Hötte GJ; Kolijn PM; de Bie M; de Keizer ROB; Medici M; van der Weerd K; van Hagen PM; Paridaens D; Dik WA
    Front Endocrinol (Lausanne); 2024; 15():1340415. PubMed ID: 38577576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated serum thyroid stimulating immunoglobulin linked to failure of first-line intravenous methylprednisolone monotherapy in moderate-to-severe thyroid eye disease.
    Zloto O; Rosset A; Priel A; Landau-Prat D; Cukierman-Yaffe T; Shavit R; Agmon-Levin N; Ben Simon GJ; Sagiv O
    Eye (Lond); 2024 Mar; 38(4):687-690. PubMed ID: 37821543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy.
    Ponto KA; Diana T; Binder H; Matheis N; Pitz S; Pfeiffer N; Kahaly GJ
    J Endocrinol Invest; 2015 Jul; 38(7):769-77. PubMed ID: 25736545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy.
    Ponto KA; Kanitz M; Olivo PD; Pitz S; Pfeiffer N; Kahaly GJ
    Ophthalmology; 2011 Nov; 118(11):2279-85. PubMed ID: 21684605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of thyroid-stimulating immunoglobulin as a biomarker of the activity of thyroid eye disease.
    Jeon H; Lee JY; Kim YJ; Lee MJ
    Eye (Lond); 2023 Feb; 37(3):543-547. PubMed ID: 35220401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid eye disease presenting with superior rectus/levator complex enlargement.
    Wang Y; Mettu P; Broadbent T; Radke P; Firl K; Shepherd JB; Couch SM; Nguyen A; Henderson AD; McCulley T; McClelland CM; Mokhtarzadeh A; Lee MS; Garrity JA; Harrison AR
    Orbit; 2020 Feb; 39(1):5-12. PubMed ID: 31056988
    [No Abstract]   [Full Text] [Related]  

  • 8. Diagnostic Utility of a New Assay for Thyroid Stimulating Immunoglobulins in Graves' Disease and Thyroid Eye Disease.
    Stan MN; Algeciras-Schimnich A; Murthy V; Thapa P; Araki N
    Thyroid; 2022 Feb; 32(2):170-176. PubMed ID: 34714163
    [No Abstract]   [Full Text] [Related]  

  • 9. Investigation of lacrimal gland and extraocular muscle in thyroid eye disease patients with severe subjective dry eye disease: a multiparametric magnetic resonance imaging study.
    Liao X; Aljufairi FMAA; Sebastian JU; Jia R; Wong HYM; Lai KKH; Chen W; Hu Z; Wei Y; Chu WCW; Tham CCY; Pang CP; Chong KKL
    Graefes Arch Clin Exp Ophthalmol; 2024 Aug; 262(8):2651-2659. PubMed ID: 38456927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
    Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
    J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy.
    Lai KKH; Aljufairi FMAA; Li CL; Ngai AKY; Yeung CSK; Fong RHY; Yip WWK; Young AL; Pang CP; Chong KKL
    J Clin Med; 2023 May; 12(9):. PubMed ID: 37176682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal correlation of thyroid-stimulating immunoglobulin with clinical activity of disease in thyroid-associated orbitopathy.
    Dragan LR; Seiff SR; Lee DC
    Ophthalmic Plast Reconstr Surg; 2006; 22(1):13-9. PubMed ID: 16418659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of clinical course with thyroid-stimulating immunoglobulin in Graves' ophthalmopathy in Mongolians.
    Bayarmunkh O; Ganbold C; Das S; Davaatseren U; Minjuurdorj NE; Jav S
    PLoS One; 2022; 17(11):e0277055. PubMed ID: 36395261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal association of thyroid-stimulating immunoglobulin levels with clinical characteristics in thyroid eye disease.
    Ko J; Kook KH; Yoon JS; Woo KI; Yang JW;
    BMJ Open; 2022 Jun; 12(6):e050337. PubMed ID: 35728893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between extraocular muscle enlargement and thyroid autoantibodies in thyroid eye disease.
    Koizumi T; Tanaka T; Umeda K; Komiyama D; Obata H
    Jpn J Ophthalmol; 2024 May; 68(3):250-258. PubMed ID: 38609717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical challenge: An orbital Hickam's dictum.
    Wilson ME; Thornton S; Murchison AP; Bilyk JR
    Surv Ophthalmol; 2016; 61(6):799-805. PubMed ID: 26994869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost.
    Park J; Kim J; Ryu D; Choi HY
    Front Endocrinol (Lausanne); 2023; 14():1079628. PubMed ID: 36817584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole.
    Liu K; Fu Y; Li T; Liu S; Chen D; Zhao C; Shi Y; Cai Y; Yang T; Zheng X
    Clin Biochem; 2021 Nov; 97():34-40. PubMed ID: 34331946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between extraocular muscle size and motility restriction in thyroid eye disease.
    Dagi LR; Zoumalan CI; Konrad H; Trokel SL; Kazim M
    Ophthalmic Plast Reconstr Surg; 2011; 27(2):102-10. PubMed ID: 21383547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.